Regents of the University of California’s Orexigen Therapeutics, Inc. OREX Stock Holding History

Regents of the University of California’s Portfolio OREX Stock Details OREX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2013 Q3	–	Sell	-4,220	Closed	-$247K	–	103
2013 Q2	$247K	Buy	+4,220	New	+$260K	0.13%	66

Other funds holding OREX

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Regents of the University of California's OREX Position: Q3 2013 in Review

Regents of the University of California sold out of Orexigen Therapeutics, Inc. (OREX) in Q3 2013, closing a stake of 4,220 shares — an estimated $247K sold.

Regents of the University of California first reported a position in OREX in Q2 2013 and held it in 1 quarter. The position peaked at $247K in Q2 2013. 130 funds tracked by Wall St. Rank hold OREX as of Q3 2013.

Regents of the University of California reported no remaining Orexigen Therapeutics, Inc. position as of Q3 2013 after selling out during the quarter.
Regents of the University of California sold 4,220 Orexigen Therapeutics, Inc. shares in Q3 2013, an estimated $247K.
Regents of the University of California first reported a position in Orexigen Therapeutics, Inc. in Q2 2013 and held it in 1 quarter.
Regents of the University of California's Orexigen Therapeutics, Inc. position peaked at $247K in Q2 2013.
130 funds tracked by Wall St. Rank held Orexigen Therapeutics, Inc. as of Q3 2013.

Based on Regents of the University of California's 13F filing for Q3 2013, filed 28 Oct 2013.